HIV vaccine development
8 European H2020 organizations list this as part of their work — 3 as their primary capability.
Most active in this area
- ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO
Italy's national infectious disease hospital providing clinical validation for rapid diagnostics, vaccines, and therapeutics against high-consequence pathogens.
“Partner in EHVA (European HIV Vaccine Alliance), contributing immunology and virology platforms for prophylactic and therapeutic vaccine evaluation.”
IT21 projects - JANSSEN VACCINES & PREVENTION BV
Johnson & Johnson's vaccine R&D division, developing prophylactic vaccines against Ebola, HIV, malaria, and emerging infectious diseases through large EU consortia.
“Participated in EHVA, the European HIV Vaccine Alliance, contributing immunology and virological platforms plus innovative trial design.”
NL10 projects - SANOFI PASTEUR SA
Global vaccine manufacturer contributing clinical data, manufacturing expertise, and epidemiological evidence to Europe's largest vaccine research consortia.
“EHVA — the European HIV Vaccine Alliance — where Sanofi Pasteur contributed to prophylactic and therapeutic vaccine evaluation platforms.”
FR9 projects - STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER
Dutch primate research center specializing in preclinical vaccine evaluation for infectious diseases, with deep ties to European vaccine infrastructure programs.
“EHVA (EUR 1M funding) focused specifically on HIV prophylactic and therapeutic vaccine discovery and evaluation with immunology and virological platforms.”
PrimaryNL7 projects - VACCINE FORMULATION INSTITUTE(CH)LTD
Swiss vaccine formulation institute contributing adjuvant and antigen design expertise to European HIV, malaria, and vaccine infrastructure consortia.
“EHVA was a major EU platform for prophylactic and therapeutic HIV vaccine discovery and evaluation.”
CH3 projects - EUROVACC FOUNDATION
Swiss vaccine development foundation specializing in immune monitoring, clinical trial design, and translational research for HIV, influenza, and emerging infections.
“Core participant in EHVA, a major European platform for discovering and evaluating prophylactic and therapeutic HIV vaccines.”
PrimaryCH3 projects - Instituto Nacional de Saúde
Mozambique's national health research institute specializing in TB and HIV clinical trials for European infectious disease consortia.
“Participated in EHVA, a major European HIV Vaccine Alliance platform for prophylactic and therapeutic vaccine evaluation.”
MZ3 projects - FRED HUTCHINSON CANCER RESEARCH CENTER NON PROFIT CORPORATION
US non-profit research center specializing in HIV vaccine immunology, multi-omics patient data analysis, and clinical trial design for European infectious disease consortia.
“EHVA (2016–2023) is a flagship EU HIV vaccine discovery platform, and FHCRC contributed to prophylactic and therapeutic vaccine research within it.”
PrimaryUS2 projects